Amphastar Pharmaceuticals, Inc.

For the period ended Dec 31, 2025. Filed Feb 26, 2026.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Feb 26, 2026

AMPH$29.38+3.1%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Consolidated Balance Sheets

(in thousands, except share data)


· · December 31, · · December 31,
· · 2025 · · 2024
ASSETS
Current assets:
Cash and cash equivalents	$170,177	$151,609
Restricted cash	235	235
Short-term investments	112,635	70,036
Restricted short-term investments	2,200	2,200
Accounts receivable, net	143,560	136,289
Inventories	176,890	153,741
Income tax refunds and deposits	17,167	1,747
Prepaid expenses and other assets	13,152	18,214
Total current assets	636,016	534,071

Property, plant, and equipment, net	310,567	297,345
Finance lease right-of-use assets	221	383
Operating lease right-of-use assets	42,931	46,899
Goodwill and intangible assets, net	565,965	590,660
Long-term investments	—	10,996
Other assets	31,135	25,992
Deferred tax assets	42,464	71,124
Total assets	$1,629,299	$1,577,470

LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable and accrued liabilities	$148,348	$157,057
Income taxes payable	239	9,664
Current portion of long-term debt	1,641	234
Current portion of operating lease liabilities	7,928	6,804
Total current liabilities	158,156	173,759

Long-term reserve for income tax liabilities	5,926	6,957
Long-term debt, net of current portion and unamortized debt issuance costs	608,749	601,630
Long-term operating lease liabilities, net of current portion	37,684	41,881
Other long-term liabilities	29,979	20,945
Total liabilities	840,494	845,172
Commitments and contingencies (see Note 17)
Stockholders’ equity:
Preferred stock: par value $0.0001; 20,000,000 shares authorized; no shares issued and outstanding	—	—
Common stock: par value $0.0001; 300,000,000 shares authorized; 61,779,883 and 45,645,497 shares issued and outstanding, respectively, as of December 31, 2025 and 60,847,124 and 47,617,691 shares issued and outstanding, respectively, as of December 31, 2024	6	6
Additional paid-in capital	535,380	505,400
Retained earnings	666,881	568,787
Accumulated other comprehensive loss	(5,314)	(9,181)
Treasury stock	(408,148)	(332,714)
Total stockholders' equity	788,805	732,298
Total liabilities and stockholders’ equity	$1,629,299	$1,577,470

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.